River and Mercantile buoyed by derivatives business during coronavirus sell-off
‘Approximately 60% of our revenues are not exposed to equity market beta’
Coronavirus
-
-
Mash Patel: Covid-19 crisis exposes investment sector’s tech deficiencies
History may remember the pandemic as the catalyst for profound changes in working practices in investment
-
Home working tips from Quilter Cheviot’s former submariner
William Reid explains his home working tips based on his 102 days in a Navy submarine
-
‘They seem to pale into insignificance’: Nine investors compare previous crises to coronavirus
‘I remember days in 2008 looking at the Bloomberg screen and feeling physically nauseous’
-
Financial ombudsman asks FCA for extra £38m to fund levy
30% of the Fos’s income to come from levy, up from 15% the year before
-
‘Investors rightly dislike information vacuums’: WFH – with Rathbones’ David Coombs
Continuing our regular series of how investment experts are dealing with the coronavirus fallout
-
Fundsmith EM trust adds two names on coronavirus share price falls
Feet discount neared 20% last month but NAV significantly outperformed
-
We’ve been more active than ever: Quarantine Q&A with LGIM’s Justin Onuekwusi
LGIM’s head of retail multi-asset spots opportunities in high yield and diversification beyond the ‘usual suspects’
-
How to help clients near retirement as Covid-19 spreads
If advisers haven’t reduced exposure to risk and volatility then the ‘horse has bolted’
-
Business as usual: Read Portfolio Adviser’s April issue online
Markets are still functioning despite the coronavirus lockdown and so are we
-
Rory Campbell-Lamerton: Bill Gates, Microsoft and the next epidemic
Companies bought today need to have core businesses strong enough to survive the tough times ahead
-
Link sells Woodford stock surging more than tenfold amid coronavirus outbreak
Synairgen has begun its first trial on patients for a respiratory drug to treat Covid-19
